Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-4359 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**mRNA-4359 + pembrolizumab** is an investigational combination therapy for advanced solid tumors, including melanoma and non-small cell lung cancer. mRNA-4359 is an mRNA-based cancer vaccine encoding fragments of IDO1 and PD-L1, delivered via lipid nanoparticles, designed to stimulate antigen-specific T-cell responses against tumor cells. Pembrolizumab is a monoclonal antibody targeting PD-1, acting as an immune checkpoint inhibitor to enhance anti-tumor immunity. This combination aims to amplify the immune system's response to tumors by both training immune cells to recognize cancer antigens and blocking inhibitory signals that restrain T-cell activity. The therapy is currently in Phase 1 trials for safety and efficacy, with the investigational mRNA vaccine developed by Moderna and pembrolizumab marketed by Merck[1][5][2][3][7].
- Other names
- mRNA-4359mRNA4359mRNA 4359CX-029440CX029440CX 029440pembrolizumabKeytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on mRNA-4359 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-4359 + pembrolizumab.